Protective immunity and new vaccines for lyme disease

Maria Gomes-Solecki, Paul M. Arnaboldi, P. Bryon Backenson, Jorge L. Benach, Christopher L. Cooper, Raymond J. Dattwyler, Maria Diuk-Wasser, Erol Fikrig, J. W. Hovius, Will Laegreid, Urban Lundberg, Richard T. Marconi, Adriana R. Marques, Philip Molloy, Sukanya Narasimhan, Utpal Pal, Joao H.F. Pedra, Stanley Plotkin, Daniel L. Rock, Patricia RosaSam R. Telford, Jean Tsao, X. Frank Yang, Steven E. Schutzer

Research output: Contribution to journalReview articlepeer-review


Lyme disease, caused by some Borrelia burgdorferi sensu lato, is the most common tick-borne illness in the Northern Hemisphere and the number of cases, and geographic spread, continue to grow. Previously identified B. burgdorferi proteins, lipid immunogens, and live mutants lead the design of canonical vaccines aimed at disrupting infection in the host. Discovery of the mechanism of action of the first vaccine catalyzed the development of new strategies to control Lyme disease that bypassed direct vaccination of the human host. Thus, novel prevention concepts center on proteins produced by B. burgdorferi during tick transit and on tick proteins that mediate feeding and pathogen transmission. A burgeoning area of research is tick immunity as it can unlock mechanistic pathways that could be targeted for disruption. Studies that shed light on the mammalian immune pathways engaged during tick-transmitted B. burgdorferi infection would further development of vaccination strategies against Lyme disease.

Original languageEnglish (US)
Pages (from-to)1768-1773
Number of pages6
JournalClinical Infectious Diseases
Issue number8
StatePublished - Apr 15 2020


  • Borrelia burgdorferi
  • Borreliella
  • Lyme disease
  • Vaccines

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Protective immunity and new vaccines for lyme disease'. Together they form a unique fingerprint.

Cite this